モモ wrote a post · Oct 29, 2024 07:01

Transmedics $TMDX 🫀 announces 2024 Q3 financial results‼️

Transmedics $TMDX 🫀
Announcement of 2024 Q3 earnings‼️
Achieving significant growth, but falling below market estimates 📉
Stock price drops by 24% in after-hours trading 💦

🔸 FY24 Q3 performance
❌EPS: $0.12 (compared to expected -$0.17)
❌Revenue: $0.109 billion (compared to expected -$-0.006 billion)
📈Revenue growth rate: +64% year-on-year

🔸FY24 full-year guidance (unchanged)
❌Revenue: $0.425 billion-$-0.445 billion (compared to expected -$-0.009 billion)
Revenue growth rate: +76-84% year-on-year.

Financial Highlights
Gross profit margin: 56% (61% in the same period last year).
Operating expenses: $56.9 million (last year $69 million).
Net profit: $4.2 million (profit margin 3.9%).
Cash balance: $0.3 billion 30.1 million dollars.

Business Progress
Number of owned aircraft: 18 (as of September 2024).
Expansion of the usage of OCS™ (Organ Care System).
Continued growth across all 3 organs (heart, lungs, liver).
Revenue from logistics services is also growing steadily.
Continued active investment in research and development.

🔸 Long-term outlook
By 2028, the goal is to achieve an annual total of 0.01 million cases of OCS transplants.
Further expansion of the logistics network.
Continued product innovation through research and development.
Promotion of global expansion ✔️

🔸Challenges
Decrease in gross profit margin due to increase in service revenue ratio ✔️
Cost lead for future growth ✔️
Decrease in cash balance due to inventory and facility investments ✔️

🔸Company Overview
TransMedics is a leading company in organ transplant technology.
Their innovative Organ Care System (OCS™) enables the preservation, evaluation, and transport of transplantable organs, providing more transplant opportunities to a greater number of patients.
We have developed and provide our unique warm perfusion technology for end-stage heart, lung, and liver failure patients.